Lurasidone hydrochloride

CAS No. 367514-88-3

Lurasidone hydrochloride ( —— )

Catalog No. M14263 CAS No. 367514-88-3

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 32 In Stock
10MG 51 In Stock
25MG 66 In Stock
50MG 87 In Stock
100MG 132 In Stock
200MG 213 In Stock
500MG 447 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lurasidone hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma.
  • Description
    Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α2C
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    367514-88-3
  • Formula Weight
    529.14
  • Molecular Formula
    C28H36N4O2S·HCl
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 1 mg/mL (1.88 mM)
  • SMILES
    C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Murai T, et al. Behav Brain Res. 2014 Mar 15;261:26-30.
molnova catalog
related products
  • Targocil

    Targocil is used as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) (MIC90s: 2 μg/ mL) for both MRSA and MSSA.

  • AVN-101

    A higly potent, orally bioavailable, BBB permeable 5-HT7 receptor antagonist with Ki of 153 pM, with slightly lesser potency toward 5-HT6, 5-HT2A and 5HT-2C (Ki=1.2-2.0 nM).

  • Ziprasidone hydrochl...

    A full antagonist of D2 and 5-HT2A receptors with Ki of 6.8 and 0.6 nM, respectively; also is a partial agonist of 5-HT1A, and a partial antagonist of 5-HT2C and 5-HT1D receptors.